fbpx
Get FREE U.S. Shipping on $75 Orders*

How Nucynta – an Opioid Drug – Told Us Something About the Small Fiber Neuropathy in Fibromyalgia

1 Star2 Stars3 Stars4 Stars5 Stars (2) votes, average: 5.00 out of 5
Loading...

Reprinted with the kind permission of Cort Johnson and HealthRising.

Given the concerns about the use of opioid prescription drugs, the fact that one not called Tramadol worked in fibromyalgia may not elicit much interest. One the other hand, it may have told us something about a subject of great interest in FM – small fiber neuropathy (SFN).

Tapentadol (Nucynta) is an opioid drug with some similarities to tramadol – the most widely used opioid drug in FM. Both attach to the μ-opioid receptor and increase norepinephrine levels. Unlike tramadol, though, Nucynta does not affect serotonin levels, and with its potency lying somewhere between tramadol and morphine, it’s a much stronger drug, and can produce more side effects.

I don’t believe tapentadol (Nucynta) is widely used in FM, but a fascinating FM tapentadol study has cropped up which sheds light on a seemingly entirely unrelated issue – small nerve fiber neuropathy (or polyneuropathy) – which is also found in chronic fatigue syndrome (ME/CFS) as well.

Earlier, the Dutch researchers had shown that tapentadol relieved pain in diabetes patients by enhancing the inhibitory pain pathways that run down from the brain and essentially turns off or reduces pain levels. Those same pathways – which are referred to as “conditioned pain modulation (CPM)” – have been shown many times to be impaired in FM.

In general, “pain should inhibit pain”; i.e. the same amount of heat applied twice in a row should result in a reduced sensation of pain the second time.

A balky pain inhibition response isn’t the only game in town in FM – other factors play a role – but it could play a significant role in some patients. The strength of the “conditioned pain modulation” response has even been used to predict which drugs might be helpful.

Diabetic patients, for instance, with more impaired CPM or pain inhibition pathways, benefitted more from Cymbalta (duloxetine) than those with intact pain inhibition pathways.

Since Nucynta is able to perk up the pain inhibition response, it made some sense to try it in FM.

The twist was small fiber neuropathy (SFN). SFN refers to the damage or destruction of small nerve fibers in the skin or eyes that carry sensory and/or autonomic nerve signals to the brain. No one knows why this is happening in FM, but it appears to show  up in from 40-50% of FM patients, and about the same number of ME/CFS patients.

For some reason, these researchers took it upon themselves to also assess whether or not the 34 FM patients in this placebo-controlled trial had reduced numbers of small nerve fibers in the corneas of their eyes. It was a good thing they did.

The Study

The 34 patients in the randomized, double-blinded trial were started off on 50 mg of tapentadol twice daily. Each week, the dose was increased by 50–100 mg per day, to a maximum of 250 mg, two times a day.

During each of the five visits they made to the clinic during the 4 month trial, their pain inhibition pathways were assessed using heat and cold tests.

Results

Tapentadol did improve the pain inhibition response and significantly improved pain levels, but only in one group – the fibromyalgia patients without small nerve fiber damage. In fact, a remarkable 85% of the FM patients without SFN reported a significant improvement in pain. (While the authors reported that Nucynta or tapentadol is safer than drugs like oxycodone, they recommended that it be used for 3 months or less.)

Nucynta strengthened their pain inhibition pathways, but the FM patients with SFN didn’t experience any pain relief.

While Nucynta was able to improve the pain inhibition response in the FM patients with small nerve fiber damage, they did not experience any pain relief.

A recent study that found high levels of impaired pain inhibition in FM patients with SFN gave no reason to expect anything other than a positive result from a drug like Nucynta. It just didn’t happen – leaving us with a new medical mystery.

The authors suggested that FM patients with SFN may simply be sicker and less responsive to treatment. A large SFN study coming out of the Uceyler group in Germany suggests that FM patients with SFN do tend to be quite a bit sicker. They had more severe symptoms (higher pain intensity, were more impaired by pain, had higher disease, experienced more stabbing pain sensations and numbness and, not surprisingly, more anxiety) than FM patients without SFN.

If that’s true, then Nucynta just didn’t impact enough of whatever is causing their pain to make a difference. A drug like Nucynta could be helpful, but only in conjunction with other approaches.

The authors of the study also suggested that two distinct types of FM may exist – one type with SFN – and one without. The fact that the neuropathic pain scores in the SFN group were not correlated with pain inhibition scores suggested that a different component (like SFN) was causing their neuropathic pain.

The study was small and needs to be replicated before we can have confidence in its results – but it suggests, like the studies noted above, that SFN is not, as some researchers have believed, an add-on issue of little consequence. It’s either indicative of a more severe pain inducing process overall or of a different pain inducing process.

Causes of SFN

Unfortunately we don’t know what’s causing SFN. We do know that the SFN in FM appears to be different from the small fiber problems in diabetes, but tracking down the cause has not been easy. In a recent video presentation, Dr. Uceyler, a prominent SFN and FM researcher, asserted that we need to learn a lot more about small nerve fibers in general to understand what’s happening in FM.

Daniel Clauw has suggested a kind of brain-body merger. He believes the central sensitization in the brain may actually be causing the small nerve fiber problems in the body. The tapentadol study suggested we have a chicken and egg problem: they proposed that the opposite could be happening as well – that the small nerve problems in the body could be causing central sensitization.

All this goes to show is that while SFN is found in FM (and allied diseases like ME/CFS, interstitial cystitis, irritable bowel syndrome, and Ehlers Danlos Syndrome), the bad news is that we still don’t know why it (or central sensitization) is occurring.

The good news is that interest in SFN in FM is at an all-time high with studies emerging regularly. Recently, for instance, the Uceyler group dug a little deeper into the skin to find a reduction of small nerve fibers near the blood vessels. Cautiously interpreting the finding, Ucelyer noted that the finding fit with past FM findings suggesting that the microcirculation may be affected in FM.

That’s a very intriguing possibility given Systrom’s findings suggesting that impaired microcirculation may be contributing to the energy production problems in chronic fatigue syndrome (ME/CFS). (We clearly need more SFN research in ME/CFS).

Plus, SFN is popping up in more and more diseases. It turns out that the more you look for it, the more it’s there. It’s not so surprising SFN might pop up in diseases which share similarities with FM and ME/CFS such as irritable bowel syndrome and interstitial cystitis, or that it’s also shown up in post-COVID syndrome and post-treatment Lyme syndrome. It’s also showing up in diseases like Parkinson’s, amyotrophic lateral sclerosis (ALS) and inflammatory neuropathies.

Treatment

Effective treatment is, of course, the ultimate goal. The most common treatments (antidepressants, antiseizure and/or opioid drugs, lidocaine creams) may be helpful for some but clearly aren’t getting at the heart of the problem. Some drugs that are not commonly used (flupirtine, Infliximab, adalimumab, lacosamide) may be helpful in some cases. Of the fibromyalgia drugs duloxetine (Cymbalta) and pregabalin (Lyrica) can sometimes be helpful. (If you respond to Cymbalta, it may be because you have a problem with your pain inhibition pathways.)

IVIG is an intriguing possibility, but is expensive and hard to get. It is, however, commonly used to treat SFN in immune diseases like sarcoidosis. Fibromyalgia is not usually considered an immune disease, but Oaklander believes FM is misdiagnosed in patients with SFN: she believes that FM is SFN – and has some proof that it is immune mediated.

Oaklander has reported on IVIG’s success in children with SFN. Plus, a recent small case-report series found that IVIG improved both symptoms and small nerve fiber density in people with fibromyalgia. It will take more studies, but if they are done and that trend continues, at some point insurance companies will be more likely to pay for IVIG.

While we don’t know what’s causing the SFN in FM, ME/CFS, post-treatment Lyme disease and post-COVID 19 syndrome and the treatment options aren’t exactly exciting, it’s good to interest in SFN catch on. It’s also good to know that given the right opportunity those small nerve fibers can grow back. Hopefully we’ll get more answers in the not too distant future.


About the Author: ProHealth is pleased to share information from Cort Johnson.  Cort has had myalgic encephalomyelitis /chronic fatigue syndrome for over 30 years. The founder of Phoenix Rising and Health Rising, he has contributed hundreds of blogs on chronic fatigue syndrome, fibromyalgia and their allied disorders over the past 10 years. Find more of Cort’s and other bloggers’ work at Health Rising.

share this article

rate this article

1 Star2 Stars3 Stars4 Stars5 Stars (2) votes, average: 5.00 out of 5
Loading...

share your comments

Enrich and inform our Community. Your opinion matters!

One thought on “How Nucynta – an Opioid Drug – Told Us Something About the Small Fiber Neuropathy in Fibromyalgia”

  1. Angela Vaughn Hausinger says:

    Even if this med doesn’t help those with fibro,it’s freaking fantastic that it does help someone in pain!

Leave a Reply

Your email address will not be published. Required fields are marked *

ProHealth CBD Store